Introducing Fierce Biotech's 2023 Fierce 15
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics hopes to overcome bacterial resistance with its unique and expanding library of bacteriophage therapies.
CEO: Greg Merril
Founded: 2016
Based: Gaithersburg, Maryland
Clinical focus: Bacterial infections
Apnimed
Apnimed is working to treat the underlying cause of sleep apnea with the first pharmaceutical treatment for the disease.
CEO: Larry Miller, M.D.
Founded: 2017
Based: Cambridge, Massachusetts
Clinical focus: Obstructive sleep apnea
Boundless Bio
Boundless Bio aims to improve outcomes in one of the remaining frontiers in oncology by advancing a pipeline of ecDNA-directed therapies.
CEO: Zachary Hornby
Founded: 2019
Based: San Diego
Clinical focus: ecDNA-directed medicines for cancer
Carmot Therapeutics
With a clinical pipeline of GLP-1s, Carmot hopes to develop transformative therapies for people with metabolic diseases.
CEO: Heather Turner
Founded: 2008
Based: Berkeley, California
Clinical focus: Diabetes/obesity
Cerevance
Using a collection of thousands of donated human brain tissue samples, Cerevance is developing a massive database of expression and epigenetic data to identify the best targets for central nervous system disorders.
CEO: Craig Thompson
Founded: 2016
Based: Boston
Clinical focus: Neurodegenerative diseases such as Alzheimer’s and Parkinson’s
Comanche Biopharma
Comanche is aiming RNA therapies at a pregnancy complication that impacts millions.
CEO: Scott Johnson
Founded: 2020
Based: Concord, Massachusetts
Clinical focus: Preeclampsia
Epic Bio
The biotech that's downsized a CRISPR-engineered protein to upsize its therapeutic potential has already seen interest from investors and Big Pharma.
CEO: Amber Salzman, Ph.D.
Founded: 2018
Based: South San Francisco, California
Clinical focus: Facioscapulohumeral muscular dystrophy, heterozygous familial hypercholesterolemia, alpha-1 antitrypsin deficiency, retinitis pigmentosa 4 and retinitis pigmentosa 11
FogPharma
Developing polypeptide therapies for hard-to-tackle solid tumors by targeting new intracellular targets.
CEO: Mathai Mammen, M.D., Ph.D.
Founded: 2015
Based: Cambridge, Massachusetts
Clinical focus: Advanced solid tumors
HiFiBiO Therapeutics
Identifying and developing antibodies more efficiently and expeditiously.
CEO: Liang Schweizer, Ph.D.
Founded: 2013
Based: Cambridge, Massachusetts
Clinical focus: Fusing a novel microfluid system with machine learning to swiftly discover antibody-based therapies
Orca Bio
With a precision-focused process, Orca aims to shake up the stale stem cell therapy space and eliminate the scourge of serious adverse reactions from transplants.
CEO: Ivan Dimov, Ph.D
Founded: 2016
Based: Menlo Park, California
Clinical focus: Acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome
Palleon Pharmaceuticals
Targeting sugar molecules on cell surfaces to treat cancer and inflammatory disease
CEO: Jim Broderick, M.D.
Founded: 2015
Based: Waltham, Massachusetts
Clinical focus: Palleon Pharmaceuticals is leveraging the role that cell-surface glycans play in regulating the immune response to treat diseases.
Proxygen
Proxygen is discovering molecular glue degraders to build a new avenue toward targeting proteins that were previously considered “undruggable.”
CEO: Bernd Boidol
Founded: 2020
Based: Vienna
Clinical focus: Molecular glue degraders
RayzeBio
Chasing a new generation of radiopharmaceuticals
CEO: Ken Song, M.D.
Founded: 2020
Based: San Diego
Clinical focus: Cancer radiation therapy
SparingVision
The developer of mutation-agnostic gene therapies hopes to create eye disease medicines that can address large patient populations.
CEO: Stephane Boissel
Founded: 2016
Based: Paris
Clinical focus: Genomic medicine, specializing in ocular diseases
Ventus Therapeutics
Scoping out the hidden "pockets" on proteins to shape new approaches to inflammatory diseases
CEO: Marcelo Bigal, M.D., Ph.D.
Founded: 2019
Based: Waltham, Massachusetts
Clinical focus: Structural biology and computational chemistry to develop small-molecule candidates in immunology, inflammation and neurology
Explore In-Depth Discussions Across 3 Tracks
Strategy and Dealmaking
Early-Stage Development
PR & Communications
Explore In-Depth Discussions Across 4 Tracks
Strategy and Dealmaking
Explore the dynamics of partnerships, collaborations, and investments in biotech. Examine the changing landscape of deal structures, innovative licensing models, and successful case studies of strategic alliances.
Early-Stage Development
Delve into the challenges and groundbreaking advancements in drug discovery and early-stage biotech development. Uncover the latest research methodologies, cutting-edge technologies, and innovative approaches that accelerate scientific discoveries.
PR & Communications
NEW for 2024! Examine the ever-evolving PR landscape as communications takes a more strategic role in guiding the corporate strategy. Learn how to shape the future of biotech through effective storytelling and engagement.
Preclinical & CMC
NEW for 2024! Hear from leading experts on the latest in drug discovery strategies, formulation techniques and CMC approaches. Sessions will highlight pre-IND development strategies, laboratory practices, and drug delivery that can help accelerate therapeutic development.
LAST CHANCE!
Register Now to Secure Your Spot!
The Fierce Biotech Fierce 15 Awards
Celebrate
Join us as we honor this year's top biotech innovators handpicked by Fierce Biotech editors.
Network
Connect with Fierce 15 honorees and over 500 senior biotech executives during our Fierce 15 cocktail reception.
Learn
Hear from past Fierce 15 honorees to track their journeys from start-up to the big time. Where are they now, & where are they going?
Schedule at a glance
30
Sep
Registration and Networking Breakfast
Keynote Sessions
Networking Break
General Sessions
Networking Lunch
Tracks
Strategy & Dealmaking
Tracks
Early-Stage Development
Tracks
PR & Communications
Tracks
Preclinical & CMC
Networking Break
Tracks
Strategy & Dealmaking
Tracks
Early-Stage Development
Tracks
PR & Communications
Tracks
Preclinical & CMC
Fierce 15 Panel: Where Are They Now?
Fierce 15 Awards Ceremony
Fierce 15 Reception
1
Oct
Registration and Networking Breakfast
Day 2 Keynote
General Sessions
Tracks
Strategy & Dealmaking
Tracks
Early-Stage Development
Tracks
PR & Communications
Tracks
Preclinical & CMC
Networking Break
Tracks
Strategy & Dealmaking
Tracks
Early-Stage Development
Tracks
PR & Communications
Tracks
Preclinical & CMC
Networking Lunch
General Sessions
Conference Concludes
Two Dedicated Tracks:
Strategy and Dealmaking
Join thought leaders, industry experts, investors, and executives to explore the intricacies of biotech strategy and the art of dealmaking. Take a deep dive into the changing landscape of deal structures, innovative licensing models, and successful case studies of strategic alliances.
Early-Stage Development
Uncover the latest research methodologies, cutting-edge technologies, and innovative approaches that accelerate the progression of promising scientific discoveries. From novel drug targets and therapeutic modalities to advanced preclinical models and trial design, sessions will cover a wide spectrum of topics that are pivotal to success in early-stage development.
Register Now | Limited Passes Are Available
View the Best of the Fierce Biotech Summit 2022 On-Demand
Find the Most Relevant Topics from Our Most Popular Sessions
Search by speaker name, company, or topic. Find exactly what you're looking for and discover why you need to join us in Boston this October!